A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06136559
Trial Phases:	Phase III	Protocol IDs:	1026-011 (primary) NCI-2024-01890 2022-501697-19 2022-501697-19-00 BELLWAVE-011 jRCT2031230697 MK-1026-011 U1111-1281-7895
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06136559

Summary

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice
of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The
primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or
acalabrutinib with respect to objective response rate (ORR) per International Workshop on
Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review
(BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to
progression free survival (PFS) per iwCLL Criteria 2018 by BICR.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.